Continuum in progression of HFrEF: Addressing unmet needs with Vericiguat

Heart failure with reduced ejection fraction (HFrEF) is a progressive and debilitating condition with significant morbidity and mortality. Despite advancements in heart failure management, many patients continue to experience worsening symptoms and poor outcomes, highlighting critical unmet needs. This course focuses on the continuum of HFrEF progression and explores the role of Vericiguat, an innovative therapy targeting the underlying pathophysiology. Participants will gain insights into the clinical benefits, mechanisms of action, and practical applications of Vericiguat in addressing these gaps, ultimately improving care for patients with HFrEF.

By

Prof. Paul W Armstrong

Current Status
Not Enrolled
Price
Free
Get Started

Heart failure with reduced ejection fraction (HFrEF) is a progressive and debilitating condition with significant morbidity and mortality. Despite advancements in heart failure management, many patients continue to experience worsening symptoms and poor outcomes, highlighting critical unmet needs. This course focuses on the continuum of HFrEF progression and explores the role of Vericiguat, an innovative therapy targeting the underlying pathophysiology. Participants will gain insights into the clinical benefits, mechanisms of action, and practical applications of Vericiguat in addressing these gaps, ultimately improving care for patients with HFrEF.

Course Content

Continuum in progression of HFrEF: Addressing unmet needs with Vericiguat

Presented by

Prof. Paul W Armstrong

MD, FCAHS, FRSC

Principal Investigator, VICTORIA Trial, Professor, Division of Cardiology, Founding Director, Canadian VIGOUR Centre University of Alberta